Analyst Price Targets — DERM
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 25, 2025 10:04 am | Brandon Folkes | H.C. Wainwright | $13.00 | $7.40 | TheFly | Journey Medical initiated with a Buy at H.C. Wainwright |
| March 27, 2025 11:32 am | — | Industrial Alliance Securities | $10.50 | $5.92 | TheFly | Journey Medical price target lowered to $10.50 from $11 at Alliance Global Partners |
Latest News for DERM
Elite Pharmaceuticals and Journey Medical follow different growth paths, but which looks more compelling now? Let's dive in.
Journey Medical demonstrates strong Emrosi prescription growth, rebounding from Q1 lows with Q2 revenues up 23% to $18.5M and positive EBITDA. DERM's Emrosi franchise is gaining traction, with prescribers rising over 40% quarter-over-quarter and formulary coverage improving from 34% to 38%. Cost discipline is evident as SG&A declined and operating expenses rose less than 1%, while Emrosi's ASP and market penetration…
Journey Medical Corporation (DERM) Q2 2026 Earnings Call Transcript
The headline numbers for Journey Medical (DERM) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DERM.
U.S. House Trading
No House trades found for DERM.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.